大洋生物(003017) - 2023 Q1 - 季度财报

Financial Performance - The company's revenue for Q1 2023 was ¥251,292,978.42, representing a 29.50% increase compared to ¥194,049,118.38 in the same period last year[5] - Net profit attributable to shareholders increased by 130.06% to ¥19,396,982.24 from ¥8,431,349.53 year-on-year[5] - The net profit after deducting non-recurring gains and losses surged by 208.04% to ¥16,857,203.39 from ¥5,472,352.56 in the previous year[5] - The basic and diluted earnings per share rose by 142.86% to ¥0.34 from ¥0.14 in the same quarter last year[5] - Total operating revenue for Q1 2023 was CNY 251,292,978.42, an increase of 29.5% compared to CNY 194,049,118.38 in Q1 2022[19] - Net profit for Q1 2023 reached CNY 19,396,982.24, representing a significant increase of 130.5% from CNY 8,431,349.53 in Q1 2022[20] - The company reported a total profit of CNY 21,491,572.34 for Q1 2023, an increase of 131.5% from CNY 9,298,059.67 in the same period last year[20] Cash Flow and Assets - The net cash flow from operating activities improved by 42.57%, reaching -¥22,210,464.08 compared to -¥38,672,236.24 in the previous year[10] - The company's current assets totaled CNY 756,131,103.20, up from CNY 728,163,051.42, indicating an increase of about 3.8%[16] - The cash and cash equivalents decreased to CNY 96,847,409.95 from CNY 131,111,370.93, representing a decline of approximately 26.0%[16] - Cash flow from operating activities showed a net outflow of CNY 22,210,464.08, an improvement from a net outflow of CNY 38,672,236.24 in Q1 2022[23] - Cash flow from investing activities resulted in a net outflow of CNY 48,847,080.83, slightly better than the net outflow of CNY 50,422,671.88 in the previous year[24] - Cash flow from financing activities generated a net inflow of CNY 38,786,348.38, compared to a net inflow of CNY 7,518,397.75 in Q1 2022[24] - The ending cash and cash equivalents balance for Q1 2023 was CNY 96,847,409.95, an increase from CNY 50,191,666.37 at the end of Q1 2022[24] Assets and Liabilities - The total assets at the end of the reporting period were ¥1,532,488,497.61, a 1.63% increase from ¥1,507,973,920.76 at the end of the previous year[5] - The company's short-term borrowings rose to CNY 295,320,000.00 from CNY 252,114,104.19, marking an increase of about 17.1%[17] - The total liabilities increased slightly to CNY 527,313,683.25 from CNY 522,924,492.77, showing a marginal rise of approximately 0.7%[17] - The equity attributable to the owners of the parent company reached CNY 1,005,174,814.36, up from CNY 985,049,427.99, reflecting an increase of about 2.3%[17] Investments and Shareholder Information - The company reported a significant increase in long-term equity investments by 259.91%, amounting to ¥9,000,893.39 from ¥2,500,893.39[9] - The number of ordinary shareholders at the end of the reporting period was 10,287[12] Operational Developments - The company plans to implement a project for producing 50,000 tons/year of potassium carbonate from fly ash, which has received preliminary approval from the Hangzhou Ecological Environment Bureau[14] - Zhejiang Dayang completed the merger with its wholly-owned subsidiary Shanghai Taiyang Chemical Co., Ltd., optimizing its management structure and improving operational efficiency[14] Inventory and Receivables - The company reported an increase in accounts receivable to CNY 76,896,923.33 from CNY 68,990,582.76, which is an increase of approximately 11.0%[16] - Inventory levels rose to CNY 138,843,313.02 from CNY 126,871,327.15, indicating an increase of about 9.4%[16] Research and Development - Research and development expenses for Q1 2023 totaled CNY 8,499,851.91, up 28.9% from CNY 6,594,699.94 in Q1 2022[19]